COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 3 of 3 for:    pegzilarginase

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency (AEB1102)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03378531
Recruitment Status : Active, not recruiting
First Posted : December 20, 2017
Last Update Posted : January 10, 2020
Information provided by (Responsible Party):
Aeglea Biotherapeutics

Brief Summary:
The purpose of this study is to investigate the long-term safety, tolerability, immunogenicity, pharmacokinetics and pharmacodynamics of intravenous AEB1102 in patients who complete Study CAEB1102-101A.

Condition or disease Intervention/treatment Phase
Arginase I Deficiency Hyperargininemia Drug: AEB1102 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A
Actual Study Start Date : December 7, 2017
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021

Arm Intervention/treatment
Experimental: AEB1102
Each patient may receive AEB1102 administered IV for up to approximately 3 years.
Drug: AEB1102
modified human arginase I
Other Names:
  • Co-ArgI-PEG
  • Pegzilarginase

Primary Outcome Measures :
  1. Incidence of treatment-related adverse events [ Time Frame: up to 3 years ]

Secondary Outcome Measures :
  1. Cmax Cmin [ Time Frame: up to 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Complete treatment in Study CAEB1102-101A without experiencing any clinically significant adverse event or other unmanageable drug toxicity that would preclude continued dosing
  2. Confirmation by the Investigator and the Sponsor determine that it is acceptable for the patient to continue dosing with AEB1102
  3. If female and of child-bearing potential, has a negative serum pregnancy test within 7 days before enrollment
  4. If sexually active (male or female), must be surgically sterile, post-menopausal (female), or must agree to use a physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration
  5. Patient or legal guardian is able and willing to provide written informed consent and where required assent, and to comply with all requirements of study participation (including all study procedures and continuation of prescribed diet without modification), prior to any screening procedures

Exclusion Criteria:

1. Clinically significant concurrent disease, serious intercurrent illness, or other extenuating circumstances

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03378531

Layout table for location information
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
United States, Florida
University of Florida
Gainesville, Florida, United States, 32610
United States, New York
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
United States, Texas
Dallas, Texas, United States, 75390
Canada, Ontario
The Hospital for Sick Children
Toronto, Ontario, Canada, M5G 1X8
Centro Hospitalar S. Joao
Porto, Portugal
United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Sponsors and Collaborators
Aeglea Biotherapeutics
Layout table for investigator information
Study Director: Josie Gayton Aeglea Biotherapeutics, Inc.
Layout table for additonal information
Responsible Party: Aeglea Biotherapeutics Identifier: NCT03378531    
Other Study ID Numbers: CAEB1102-102A
First Posted: December 20, 2017    Key Record Dates
Last Update Posted: January 10, 2020
Last Verified: January 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urea Cycle Disorders, Inborn
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases